TTM
$33.46B
YoY change
+83.5%
5Y CAGR
+25.7%
Peak year (2025)
$27.94B
Cumulative EBITDA
$218.65B
EBITDA history chart for Eli Lilly (LLY) from 1985 to 2025
Latest: $27.94B
EBITDA growth chart for Eli Lilly (LLY) from 1985 to 2025
Latest: +83.5%
EBITDA history table for Eli Lilly (LLY) from 1985 to 2025
| 2025 | $27.94B | +83.5% | +$12.71B | ||
| 2024 | $15.23B | +77.7% | +$6.66B | ||
| 2023 | $8.57B | -1.1% | −$92.70M | ||
| 2022 | $8.66B | +7.7% | +$617.60M | ||
| 2021 | $8.04B | -9.8% | −$870.50M | ||
| 2020 | $8.91B | +29.2% | +$2.01B | ||
| 2019 | $6.90B | +24.7% | +$1.37B | ||
| 2018 | $5.53B | +35.0% | +$1.43B | ||
| 2017 | $4.10B | -19.0% | −$958.70M | ||
| 2016 | $5.06B | +15.5% | +$676.90M | ||
| 2015 | $4.38B | -3.3% | −$149.20M | ||
| 2014 | $4.53B | -39.6% | −$2.97B | ||
| 2013 | $7.50B | +6.3% | +$446.80M | ||
| 2012 | $7.05B | +2.0% | +$139.10M | ||
| 2011 | $6.91B | -14.1% | −$1.13B | ||
| 2010 | $8.04B | +16.2% | +$1.12B | ||
| 2009 | $6.92B | +15874.4% | +$6.87B | ||
| 2008 | $43.30M | -99.3% | −$5.81B | ||
| 2007 | $5.85B | +18.7% | +$923.60M | ||
| 2006 | $4.93B | +12.6% | +$552.20M | ||
| 2005 | $4.38B | +2.8% | +$118.80M | ||
| 2004 | $4.26B | +5.1% | +$205.90M | ||
| 2003 | $4.05B | +6.0% | +$229.60M | ||
| 2002 | $3.82B | -8.7% | −$364.00M | ||
| 2001 | $4.18B | +4.7% | +$189.20M | ||
| 2000 | $4.00B | +5.1% | +$192.10M | ||
| 1999 | $3.80B | +14.7% | +$488.50M | ||
| 1998 | $3.31B | +12.4% | +$366.70M | ||
| 1997 | $2.95B | +13.9% | +$360.40M | ||
| 1996 | $2.59B | +2.1% | +$52.30M | ||
| 1995 | $2.54B | +13.8% | +$308.40M | ||
| 1994 | $2.23B | +111.9% | +$1.18B | ||
| 1993 | $1.05B | -31.0% | −$472.70M | ||
| 1992 | $1.52B | -26.3% | −$544.20M | ||
| 1991 | $2.07B | +15.7% | +$280.90M | ||
| 1990 | $1.79B | +28.2% | +$392.80M | ||
| 1989 | $1.39B | +11.5% | +$143.30M | ||
| 1988 | $1.25B | +60.5% | +$471.50M | ||
| 1987 | $779.30M | -24.9% | −$258.70M | ||
| 1986 | $1.04B | +15.3% | +$137.40M | ||
| 1985 | $900.60M | — | — |
- 2025$27.94B+83.5%
- 2024$15.23B+77.7%
- 2023$8.57B-1.1%
- 2022$8.66B+7.7%
- 2021$8.04B-9.8%
- 2020$8.91B+29.2%
- 2019$6.90B+24.7%
- 2018$5.53B+35.0%
- 2017$4.10B-19.0%
- 2016$5.06B+15.5%
- 2015$4.38B-3.3%
- 2014$4.53B-39.6%
- 2013$7.50B+6.3%
- 2012$7.05B+2.0%
- 2011$6.91B-14.1%
- 2010$8.04B+16.2%
- 2009$6.92B+15874.4%
- 2008$43.30M-99.3%
- 2007$5.85B+18.7%
- 2006$4.93B+12.6%
- 2005$4.38B+2.8%
- 2004$4.26B+5.1%
- 2003$4.05B+6.0%
- 2002$3.82B-8.7%
- 2001$4.18B+4.7%
- 2000$4.00B+5.1%
- 1999$3.80B+14.7%
- 1998$3.31B+12.4%
- 1997$2.95B+13.9%
- 1996$2.59B+2.1%
- 1995$2.54B+13.8%
- 1994$2.23B+111.9%
- 1993$1.05B-31.0%
- 1992$1.52B-26.3%
- 1991$2.07B+15.7%
- 1990$1.79B+28.2%
- 1989$1.39B+11.5%
- 1988$1.25B+60.5%
- 1987$779.30M-24.9%
- 1986$1.04B+15.3%
- 1985$900.60M—
EBITDA values are taken from Eli Lilly's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at Eli Lilly (LLY)
According to Eli Lilly's latest reported financial statements, the company's current EBITDA (TTM) is $33.46B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of Eli Lilly (LLY) EBITDA is $27.94B – surged 83.5% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Eli Lilly EBITDA compounded at +25.7% per year, sustaining 2 straight years of year-over-year growth.
2025 marks the peak EBITDA at $27.94B, with the historical low of $43.30M recorded in 2008.
Eli Lilly EBITDA by Year
Eli Lilly EBITDA 2025: $27.94B
Eli Lilly EBITDA in 2025 was $27.94B, surged 83.5% from 2024. This figure represents the highest annual value in the available history.
Eli Lilly EBITDA 2024: $15.23B
2024's EBITDA for Eli Lilly came in at $15.23B, surged 77.7% from 2023.
Eli Lilly EBITDA 2023: $8.57B
Eli Lilly posted EBITDA of $8.57B in 2023, edged down 1.1% below 2022.
Eli Lilly EBITDA 2022: $8.66B
In 2022, Eli Lilly reported EBITDA of $8.66B, grew 7.7% from 2021.
Eli Lilly EBITDA 2021: $8.04B
Eli Lilly EBITDA in 2021 was $8.04B.
See more financial history for Eli Lilly (LLY).
Sector peers by EBITDA
Healthcare peers of Eli Lilly (LLY), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $24.43B | |
| $23.06B | |
| $19.83B | |
| $17.63B | |
| $16.90B | |
| $11.47B |
- $41.05B
- $28.26B
- $24.43B
- $23.06B
- $19.83B
- $17.63B
- $16.90B
Frequently asked questions
Eli Lilly (LLY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation